Palleon Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Palleon Pharmaceuticals's estimated annual revenue is currently $7.4M per year.
- Palleon Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Palleon Pharmaceuticals has 48 Employees.
- Palleon Pharmaceuticals grew their employee count by -13% last year.
Palleon Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | CEO and Founder | Reveal Email/Phone |
3 | VP, Intellectual Property and Strategy | Reveal Email/Phone |
4 | VP Clinical Development | Reveal Email/Phone |
5 | VP, Head Regulatory Affairs and Quality | Reveal Email/Phone |
6 | VP, Biologics Discovery and Engineering | Reveal Email/Phone |
7 | VP CMC | Reveal Email/Phone |
8 | SVP, Operations And Finance | Reveal Email/Phone |
9 | Head Translational Medicine, Executive Director | Reveal Email/Phone |
10 | Director | Reveal Email/Phone |
Palleon Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Palleon Pharmaceuticals?
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company's proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
keywords:N/A
N/A
Total Funding
48
Number of Employees
$7.4M
Revenue (est)
-13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Palleon Pharmaceuticals News
--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.1M | 48 | 4% | N/A |
#2 | $4.6M | 48 | 2% | N/A |
#3 | $10.4M | 48 | 2% | N/A |
#4 | $3.8M | 49 | 0% | $126.6M |
#5 | $12.9M | 49 | -11% | N/A |